In addition, some of the cell lines used (BON, QGP1) have been characterized with regards to their genetic profile and have been shown to feature mutations untypical of neuroendocrine tumors or even neuroendocrine cancers (e.g. in TP53, TSC2) (48, 49). The gene discussed is TP53; the disease is neuroendocrine carcinoma.